November 19th, 2010
Posted by Caroline Popper, M.D., M.P.H.
At Popper and Company, we agree with the great scientific mind Carl Sagan who once said, “It is the tension between creativity and skepticism that has produced the stunning and unexpected findings of science.” As consultants to the life sciences industry, we recognize that those of you running biotech, pharma, medical device and medical diagnostics companies – as well as members of the investment community seeking to fund the next breakthrough – deal each working day with the creativity and skepticism inherent within life sciences.
On top of that, no one could deny that this is a dynamic time for our industry and that technologies from across many platforms are converging to change the landscapes of science and medicine. With this in mind, we are proud to announce the launch of both our new Popper and Company website and this blog. Here, I and the rest of the Popper team (Ken Walz, Shane Climie and Patti Doherty) will share our thoughts on the business implications of evolutionary trajectories in life sciences – such as renewed emphasis on clinical utility and cost effectiveness or the partnering of diagnostics with therapeutics – just as we typically do for our clients on a regular basis. Sharing these thoughts via the blog is new to us; but the focus on industry trends and strategies is in the very DNA of our firm’s culture.
Read the rest of this entry »